Submitted by endpointsnews6292 in business
California biotech Kyverna Therapeutics will garner $319 million from its Thursday morning Nasdaq debut as it rides a small but welcome wave of investor enthusiasm for initial public offerings. The mid-stage cell therapy maker priced at $22 apiece, selling 14…